Leerink Partnrs Raises Earnings Estimates for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for shares of Exact Sciences in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.81 per share for the year, up from their prior forecast of $0.80. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share.

Other equities research analysts also recently issued research reports about the company. Craig Hallum dropped their target price on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Stifel Nicolaus dropped their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Evercore ISI reduced their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Jefferies Financial Group increased their price target on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. One analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and an average target price of $72.94.

Exact Sciences Stock Up 4.9 %

Shares of EXAS stock opened at $54.26 on Wednesday. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The firm’s 50 day moving average is $57.24 and its 200 day moving average is $59.38.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $708.66 million for the quarter, compared to analysts’ expectations of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm’s revenue was up 12.8% compared to the same quarter last year.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now owns 1,074,191 shares of the company’s stock, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.36% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

Several institutional investors and hedge funds have recently made changes to their positions in EXAS. WCM Investment Management LLC boosted its position in Exact Sciences by 1,153.2% during the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after buying an additional 172,821 shares during the period. Simplify Asset Management Inc. boosted its holdings in Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares during the period. Zacks Investment Management bought a new position in Exact Sciences during the 3rd quarter worth approximately $2,083,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Exact Sciences by 59.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after purchasing an additional 125,192 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Exact Sciences by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.